Viridian Therapeutics to Participate in the Wedbush PacGrow Healthcare Virtual Conference
August 05, 2021 08:30 ET
|
Viridian Therapeutics, Inc.
BOULDER, Colo., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but...
Viridian Therapeutics Appoints Kristian Humer as Chief Financial Officer and Chief Business Officer
July 26, 2021 07:30 ET
|
Viridian Therapeutics, Inc.
BOULDER, Colo., July 26, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but...
Viridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Directors and as Chair of the Audit Committee
July 15, 2021 16:05 ET
|
Viridian Therapeutics, Inc.
BOULDER, Colo., July 15, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but...
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 14, 2021 08:00 ET
|
Viridian Therapeutics, Inc.
BOULDER, Colo., July 14, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (“the “Company” or “Viridian”), a biopharmaceutical company advancing new treatments for patients...
Viridian Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference
July 07, 2021 08:00 ET
|
Viridian Therapeutics, Inc.
BOULDER, Colo., July 07, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but...
Viridian Therapeutics to Participate in the JMP Securities Life Sciences Conference
June 10, 2021 08:00 ET
|
Viridian Therapeutics, Inc.
BOULDER, Colo., June 10, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but...
Viridian Therapeutics to Participate in Upcoming Investor Conferences
May 14, 2021 08:00 ET
|
Viridian Therapeutics, Inc.
BOULDER, Colo., May 14, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but...
Viridian Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates
May 06, 2021 16:05 ET
|
Viridian Therapeutics, Inc.
VRDN-001 and VRDN-002 programs for Thyroid Eye Disease (TED) progressing; on track for IND filings in fourth quarter of 2021Reported $117 million in cash, cash equivalents and short-term investments...
Viridian Therapeutics Reports 2020 Financial Results and Provides Corporate Updates
March 25, 2021 16:05 ET
|
Viridian Therapeutics, Inc.
Progressed lead programs VRDN-001 and VRDN-002 towards clinical trials in Thyroid Eye Disease (TED); both IND filings expected by the end of 2021 Completed integration and name change to Viridian...
Viridian Therapeutics To Host Conference Call Discussing Fourth Quarter And Full Year 2020 Results And Corporate Update
March 09, 2021 16:30 ET
|
Viridian Therapeutics, Inc.
BOULDER, Colo., March 09, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but...